Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma

被引:1
|
作者
Cao, Yenong [1 ]
Afzal, Muhammad Zubair [2 ]
Shirai, Keisuke [2 ]
机构
[1] Dartmouth Hitchcock Med Ctr, Dept Internal Med, Lebanon, NH 03766 USA
[2] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
关键词
skin cancer; unwanted effects; adverse reactions;
D O I
10.1136/bcr-2021-243713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mucosal melanoma is a rare subtype of melanoma and represents a unique diagnosis and treatment challenge. Immune-checkpoint inhibitors (ICIs) have revolutionised metastatic melanoma treatment, and one of the leading regimens is the combination of ipilimumab (anti-cytotoxic T lymphocyte-associated antigen 4: CTLA4) and nivolumab (anti-programmed cell death protein 1: PD1). We report a case of a patient with metastatic mucosal melanoma treated with ipilimumab and nivolumab who developed multiple immune-related adverse events (irAEs) including uveitis, type I diabetes complicated by diabetic ketoacidosis, destructive thyroiditis, hepatitis and vitiligo. Endocrinopathies including type 1 diabetes and hypothyroidism were treated with insulin and levothyroxine. Hepatitis was responsive to steroids. She had sustained complete response 12 months after discontinuation of the combination therapy. With the wide usage of ICIs in multiple types of malignancies, it is important for general practioners to recognise common and serious irAEs due to ICIs.
引用
收藏
页数:3
相关论文
共 50 条
  • [21] Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
    Tirumani, Sree Harsha
    Ramaiya, Nikhil H.
    Keraliya, Abhishek
    Bailey, Nancy D.
    Ott, Patrick A.
    Hodi, F. Stephen
    Nishino, Mizuki
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) : 1185 - 1192
  • [22] IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH BETTER SURVIVAL OUTCOMES FOR METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB PLUS IPILIMUMAB
    Numakura, Kazuyuki
    Hatakeyama, Shingo
    Sekine, Yuya
    Muto, Yumina
    Kobayashi, Mizuki
    Kashima, Soki
    Yamamoto, Ryohei
    Koizumi, Atsushi
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2022, 207 (05): : E175 - E175
  • [23] Nivolumab in resected and unresectable melanoma: Immune-related adverse events and association with survival outcomes
    Freeman-Keller, Morganna L.
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [24] A CASE OF A NEUROLOGICAL IMMUNE-RELATED ADVERSE EVENT ASSOCIATED WITH IPILIMUMAB/NIVOLUMAB
    Walker, Josh
    Farag, Mena
    Josephs, Debra
    Williams, Victoria
    Holmes, Paul
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [25] Severe immune-related adverse events (irAE) induced by nivolumab at our institution
    Hasegawa, Yoshikazu
    Tsukuda, Hiroshi
    Ota, Takayo
    Miyatake, Nozomi
    Matsui, Kaoru
    Fukuoka, Masahiro
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.
    Esfahani, Khashayar
    Thebault, Pamela
    Lapointe, Rejean
    Jamal, Rahima
    Miller, Wilson H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab
    Olson, Daniel J.
    Rajagopal, Padma
    Tjota, Melissa Y.
    Venkataraman, Girish
    Luke, Jason J.
    Gajewski, Thomas F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [28] Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab
    Remolina-Bonilla, Yuly A.
    Jimenez-Franco, Brenda
    Lam, Elaine T.
    Bourlon, Maria T.
    ONCOLOGY-NEW YORK, 2020, 34 (05): : 171 - 174
  • [29] Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
    Weber, Jeffrey S.
    Kaehler, Katharina C.
    Hauschild, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) : 2691 - 2697
  • [30] Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma
    Tasaki, Yoshihiko
    Hamamoto, Shuzo
    Sugiyama, Yosuke
    Tomiyama, Nami
    Naiki, Taku
    Etani, Toshiki
    Taguchi, Kazumi
    Matsuyama, Nayuka
    Sue, Yasuhito
    Mimura, Yoshihisa
    Kubota, Hiroki
    Noda, Yusuke
    Aoki, Maria
    Moritoki, Yoshinobu
    Nozaki, Satoshi
    Kurokawa, Satoshi
    Okada, Atsushi
    Kawai, Noriyasu
    Yasui, Takahiro
    Kimura, Kazunori
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (10) : 866 - 874